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Introduction
Molecular vaccines, as defined in this review, are vaccines rhac are rationally designed at the molecular level to induce long term immunity, optimally comprising both antibody and T cell-mediated responses specifically targeting one or more protective antigens. Molecular vaccines are to be contrasted with whole organism vaccines, either attenuated or inactivated, for which underlying molecular components have not been characterized. While attenuated whole organism vaccines constitute the majority of vaccines currently licensed for human use, they can be viewed as occupying one end of a spectrum of approaches to vaccine development, namely the empirical selection and testing of an immunogen
•correspondence to: joseph T. Bruder; Email: jbruder@genvec.com Submitted: I 0/20/09; Accepted: I 0/29/09 Previously published online: www.landesbioscience.com/journals/vaccines/article/10463 binding interactions mediating host cell entry, cytoadherence, ·' n~t~ient. up~aKe, ~tc.), (3) id~ntification of specific target molecules based on this concept {e.g.,-t:he parasite ligand binding to " the-hosr-receptor),--(4) identificatiort of an immune response able to target the key parasite molecules and interrupt the pathogenic process, and (5) development of an appropriate vaccine delivery system, immunogen(s) and formulation capable of inducing the required, antigen-specific, protective immune responses. Figure 1 compares these two divergent approaches.
While we have few examples of licensed molecular vaccines, the approach is appealing, especially for potentially lethal pathogens such as HIV where the development of attenuated whole organism vaccines entails daunting safety concerns, and for pathogens where the development of attenuated vaccines is limited by the difficulty with in vitro production such as malaria. Parasites fall primarily into the latter category-they are difficult to culture and in addition, crude preparations of parasite antigens, such as killed parasites or parasite lysates have proven minimally protective, probably because the natural infection itself often fails to induce sterilizing immunity. This lack of naturally-induced sterile protection reflects the many adaptations by parasites enabling them to circumvent the host immune response, thereby permitting establishment of the chronic infections required to achieve transmission. presence of multiple parasite-host molecular interfaces (allowing the concepru alization of many opporrunitics for molecula r-based intervention), good anima l models and the ability to safely challenge humans with infectious sporozoites to look for protection, which strongly facilitates rhe iterative resring and refi nement of molecular-based vaccine concepts. Even with a molecular approach, however, malaria's complex life cycle and immune invasion adaptations pose extraordinary challenges for the vaccine developer.
Many of the vaccines discussed in this issue of Human Vaccines are molecular in nature, including pregnancy-~pec i fic vaccines based on interruption of binding ro placenta l chondroitin sulfate A (reviewed by Menendez er al., 21 ), transmission-blocking vaccines aimed at inducing antibod y responses to sexual stage su rface antigens (d iscussed in reviews by Robert Sinden, p. 3 and Birkerr p. 139), asexual srage vaccines aimed at inducing antibody responses to variable antigens expressed on the surface of infected erythrocytes (reviewed by Hviid p. 84) and recombinant protein-based vaccines composed of immunodominant proteins, sometimes wirh well-d escribed functions (reviewed by Anders et al. p. 39) . RTS,S (reviewed by Coh en er al., p. 90) is a p:micularly elegant exa mple of molecular design applied to a recombi nant prote in , combin ing rational antigen choice (the vaccine uses a major surface protein of the sporozoite, ca lled the ci rcumsporozoite protein, CSP) with construction of a fusion gene incorporaring the rarget antigen linked to hepatitis B surface antigen, which facilitates self-assembly of the yeast-produced protein into highly immunogenic particles.:
Importantly, RTS,S has shown protection in severa l Phase 2 field trials and rhereby demons tr:ues rhe feas ibi lity o f developing a molecular vaccine thar protects against malaria. Other vaccines reviewed in this issue, such as whole sporozoires generica lly at tenuated by targeted gene deletion (reviewed by Vaughan er al., p. I 07), although based on empiric srraregies, incorporate molecular techniques and rhus could b e considered molecu lar in design.
To avoid dupl ication with these accounts of molecular vaccines and molecular approaches, this article focuses on molecular technologies nor discussed in d erai l elsewhere, wirh an emphasis on gene-based vaccine platforms, such as DNA and viral vectors. lr is organized into six sections. rhe first five emphasizing major vaccine components where molecular design can be applied: (1) antigen design, (2) adjuvant design, (3) vaccine delivery systems, (4) viruslike particles and (5) safety. The review concludes with a d iscussion of specific challenges in molecu la r vaccine development for a parasite that has evolved over millions of years to persisr in human populations (6).
vaccines. For example, both recombinant protein-and gene-based based vaccines. Our results indicate that adenovector-mediated vaccines are candidates for codon optimization or harmoniza-expression of AMAl and MSP1 42 (42 kilodalton fragment of tiontt to enable improved expression in the relevant production MSPl) at the cell surface is associated with improved magnitude cell line or in humans, and may benefit from additional cus-and functionality of antibody responses relative to intracellular tomized alterations for increasing antibody or T cell responses. expression. 6 This finding is in agreement with other published Several of the most important aspects to antigen design are dis-data for DNA and poxvirus vectored vaccines. In contrast, induecussed in this section.
tion of AMAl and MSP1 42 -specific T cell responses following Molecular modification of antigen expression, localiza-adenovector delivery was not affected by subcellular localization tion, secondary processing and intrinsic antigenic proper-of antigen. ties to improve immunogenicity. The low GC content of the Another factor that could significantly influence immunoge-P. folciparum genome ( .... 20% relative to .... 40% for humans) is nicity is the presence or absence of glycosylation sites. P. foldassociated with different patterns of codon utilization compared parum parasites do not contain significant amounts of N-linked to the genes of humans. These different codon usage patterns and 0-linked carbohydrates. 7 However, when produced in, or can negatively impact transgene expression and immunogenicity delivered to eukaryotic cells with viral-or plasmid-based delivassociated with DNA and viral vectors expressing P. folciparum ery systems, many P. folciparum proteins, such as AMAl and genes in vivo. One of the simplest, most effective ways to increase MSPl, are expected to be glycosylated. Non-native glycosylation protein expression is to synthesize a new gene encoding the same of these antigens could obscure or alter key epitopes derived from amino acid sequence, but with codons that are preferentially used the tertiary structure of these blood stage antigens, and induce by the species receiving the vaccine (e.g., human, mouse, mon-antibody responses that are inferior to responses that would be ·key). Codon optimization has been shown to enhance protein observed with non-glycosylated antigens. Consistent with this, it expression of HIVl and malaria genes encoded by DNA vectors has been reported that a non-glycosylated P. folciparum MSP1 42 by 4-1,000 fold and to improve the immunogenicity of these subunit protein produced in goat milk was a more effective vacvectors i.n. mice. 8 ' 11 We have
. In a study of DNA vaccines-C:ncod,lng two _f. yo~fji antigens ;nd ~ r~~~ndy_ sh_gwh t~_at adenove£tOIJ that express glycosylated verone P. folciparum antigen, a'ibody responses were enhanced sions of MSP1' 42 andAMAl induc;ed potent functional antibody for two of the three construcrs while" cell-mediateceresponses;-as -resp'onses by an in-vitro-growth inhibition assay (GIA), and that measured by interferon-gamma (IFNy) ELISpot, lymphoprolif-modification of the N-linked glycosylation sites did not improve eration and cytotoxic T lymphyocyte assays were stronger with and in some cases significantly reduced antibody responses. 6 native sequences. Protection against P. yoelii sporozoite challenge Mutation of glycosylation sites may have destroyed immunogenic was also not improved by codon optimization. 5 Thus, the deci-epitopes directly or may have had negative effects on protein foldsian whether or not to codon optimize is best made in the con-ing and structure. text of immunogenicity studies, with knowledge of the immune The CSP protein contains a glycosylphosphatidylinosiresponse required for protection. tol (GPI) anchor, which functions to attach the protein to the A second key feature for gene-based vaccines is targeting genes plasma membrane of the sporozoite. The immunogenicity of for intracellular vs. cell surface expression. Secretion or cell sur-DNA or adenovirus vectors expressing P. berghei, P. yoelii and face expression as opposed to intracellular expression of antigens P. folciparum CSP can be improved by deletion of the GPI can induce a more robust antibody response in the context of anchor sequence.l 2 • 13 We have demonstrated that an 11 amino vaccine delivery, as extracellular or surface localization leads acid C-terminal deletion, that removes the GPI anchor sequence, to antigen presentation via the exogenous antigen presentation increases PJCSP-specific antibody responses in mice and rabbits pathway. Many P. folciparum proteins, including apical mem-following adenovector delivery (JTB, unpublished data).
brane antigen-! (AMAl), merozoite surface protein-! (MSPl)
A poorly understood feature of malaria proteins is the degree to and CSP contain functional signal sequences and it may be which they have been subject to changes in amino acid sequence critical to include these in antigens that are to be delivered by in response to immunological selection pressures. Epitopes found gene-based technologies when antibody responses are the prior-within proteins that are functionally important to parasite biology ity, whereas these sequences are often deleted in subunit, protein-(such as ligands mediating host cell invasion) may have evolved, ------would be rhe evolution of highly immuno dom inant epitopes in other do mains of the protein, exemplified by rhe repeat sequences characterizing many malarial proteins. These immunogenic do mains could serve ro diverr the immune response away from the critica l functional epitopes, leavi ng t hem "i mmunologically silent." Although these various predicted features have nor been systematically described for most malaria antigens, there is a growing list of examples concordant with these principles. One is rhe ex istence of cryptic epitopes-normally immunologically silent epitopes rhar when removed from the protein microenvironment ca n induce protective responses.
Another is altered peptide ligands (T cell mimotopes)-parasire-derived domains that appear to induce inhibitory rather than protective immune responses. 18 ' 20 These antagonist peprides, which may differ in one or rwo amino acids fro m the agonistic peptide, are hypothesized to decrease rhe threshold ofT cell act ivation, induce T cell anergy, or alter the CD4 T cell phenotype from p ro-inflammatory (Th I) ro anti-inflammatory (Th 2).
1 A particularly interesting example of rhe interplay of immune selection and epirope sequence and structure is provided by AMAI, d escribed in Figure 2 . In chis case, highly polymorphic residues su rround an invariant (and possibly immunologically silent) putative binding sire. Strategies for reversing these parasite adaptations have been explored, bur much further work is needed. For example, rargered amino acid substitutions may restore rhe ability of key epitopes ro bind wirh higher affinity ro MHC molecules, or prevent rhe induction of regulatory T cells. While changing rhe amino acid structu re of a protein might induce immune responses less specific fo r the native protein, ir may be possible ro make limired substitutions rhar enhance rather rhan reduce the affinity of antibodies or T cells for the native protein (T. Husain, personal communication). Efforts to do this in malaria and other disease models have yielded m ixed resulrs, 2 1.
22 bur given rhc often poor immunogenicity of malaria epitopes, rhe concept merits further investigation . Additional methods ro focus immune responses o n protective epitopes are discussed in rhe next section, in the context of overcoming the challenges provided by antigenic polymorphism.
Molecu lar approaches to circumventing antigenic poly morphism. The malaria parasite is notable for the a ntigen ic polymorphism ex hibited by many of rhe proteins that have been developed as vaccine cand idates. Perhaps the best exa mple is the P. folciparum eryth rocyte membrane protein-! (PjEMPl), an immunodominant adhesion protein mediating cyroadherence of parasitized eryth rocytes ro rhe vascular endothelium. PfEMPI is expressed from approximately 60 different paralogous genes encoding immun ologically variant versions of r he antigen (var gene fam ily) . These variants are expressed, in a sequentially regulated manner, on rhe surface of protuberances char appear on the membrane of infected ery throcytes during rhc late trophozoite stages. This evasion strategy enables the escape of new variants from nemralizat ion by the antibody responses specific for preced ing variants, resulting in recurrent waves of parasitemia. Orthologs of rhe va r and similar variant gene fam ilies, such as rif stevor and Pfmc-2TM are found in many malaria species and appear robe a com mon adapr~rion resu lti ng from immune-mediated sclecrion.n 24 Strategies for designing vaccines to overcome rhe polymorphisms presented by-variant gene fami lies are discussed in rhe review by Lars Hviid.
Individual generic loci also exhibit striking allelic variat ion, typifi ed by AMAI , rhe blood stage antigen mentioned above. AMAI is a promising rarger antigen for blood stage malaria vaccine development, as demonstrated in animal challenge experiments and in epidemiological studies of humans living in endemic areas. The main issue for vaccine developers is rhar hundreds of variant alleles of AMA I have been described (Box 1) and anriboJic:s spc:cific for one allele do not efficiently cross-neutralize other strains. 25 Such polymorphism indicates both rhe potential importance of variant antigens as vaccine ca ndidates (if rhey were nor protective, they wou ld nor have been subject to immune selection) as well as rhe d ifficulty faced by vaccine developers in constructi ng a full y cross-protect ive vaccine. 249 The major portion of the molecule, the ectodomain, possesses a remarkable crystal structure characterized by a conserved central core and variable external loops formed by three different Interlocking subdomains (Fig. l) ,l5° A hydrophobic groove on the face Is surrounded by polymorphic resldues, 118 which may signify epltopes serving to divert· the immune response from cryptic epitopes formed by the potential binding site lying within the groove,l 7 AMAI illustrates the barrier facing the development of molecular vaccines posed by antigenic polymorphism. A review of AMAI identified 64 polymorphic residues based on sequences listed in GenBank. with only three of the 64 in the conserved C·termlnal cytosolic region, nine in the N-terminal pro-sequence and the large majority, 52, In the ectodomain.l5 1 This diversity likely represents only the tip of the to which the AMAI molecule sequenced from the second infection differed from that of the initial infection. This analysis has identified a relationship between the degree of genetic distance between the AMAI alleles from the first and second infection and the likelihood of clinical illness, with amino acid substitutions within the AERs appearing to be particularly important.
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If sufficient data are collected from study sites across the world, this approach should enable down-selection of naturally occurring haplotypes maximizing the degree of cross-protection.
Other vaccine developers are also using GIA to help design a broadly protective AMAI vaccine. The LMIVat NIH in collaboration with MRTC in Mali has applied a clustering algorithm to AMAI sequence data from isolates around the world and identified six distinct populations based primarily on geographic area that in limited testing have induced non-cross-protective antibodies, thus constituting a minimum requirement for the number variants needed for a vaccine. 29 The Biomedical Primate Research Center (BPRC) in The Netherlands has synthesized three "diversity covering" versions of AMAl encompassing 97% of the amino acid variability observed in nature and conducted preliminary studies in rabbits showing the induction of crossinhibitory antibodies. 30 of the vaccine or other cross-reactive haplotypes relative to those in the control group. Demonstrating allele-specific protection will provide a foundation for building a more broadly protective vaccine by enumerating the number of alleles required.
Dutta et al. at the WRAIR have explored strategies to develop a more broadly protective vaccine using an in vitro GIA and mutant AMAl proteins. They identified specific polymorphic residues that function as antigenic escape residues (AERs), meaning that polymorphisms at these sites escape cross-protection in the GIA. 27 The primary AERs map to a cluster of polymorphic resides on domain-1 (CI cluster) that induce strain-specific antibodies. Narrowing down the AMAl polymorphic sites to a small number of critical AERs is an important step in the molecular design of an AMAI immunogen{s), because it will facilitate allelic shift analyses during Phase 2b trials.
As a complementary approach, the Malaria Research and Training Centre (MRTC) in Mali in a collaboration with the University of Maryland, examined the probability that the second of two sequential infections experienced by participants in a longitudinal clinical study is symptomatic, based on the degree identification of structurally constrained, conserved epitopes " a~j~ciated ,..'o/ifh k.~Y parasite fu;c;tions. The conserved, hydrophobic trough of AMAI may play such a critical role, bind--ing/to other motectiles·involved in' merozoite invasion (Fig. 2) .
The fact that monoclonal antibodies that inhibit invasion in vitro appear to act by hindering this binding interaction 31 • 32 may indicate that protective immunity could be induced by a vaccine focusing immune responses on a single or small number of epitopes. Several approaches can be taken to targeting individual conserved epitopes. One is to "cloak" potentially diversionary epitopes (such as those surrounding the hydrophobic trough of AMAl) by coating them with non-immunogenic molecules, allowing the immune system to focus on those conserved epitopes most likely to be protective. 33 Another is to synthesize epitope stringslinked sequences of conserved epitopes designed to bind to an array of MHC molecules, allowing broad population coverage for the vaccine, selecting only the epitopes of interest. 34 These epitope strings can be designed to include complementary sets of variant epitopes from polymorphic antigens, as well as conserved epitopes. Epitope strings, however, do not provide conformational structure, so may not be suitable for inducing antibodies to a putative binding site. A third approach for addressing antigen diversity is represented by "gene shuffling", whereby a series of variant alleles are broken into short segments and then various hybrid alleles are randomly re-assembled. Multiple shuffled products are evaluated via an immunoscreening assay to down-select those inducing the most broadly neutralizing antibodies. Gene shuffling has been applied to malaria vaccines with promising results in pre-clinical studies. 35 These approaches illustrate the efficiency and versatility of multi-stage vaccine was confirmed in a second study where the molecular design for malaria vaccine development when applied to interval between the DNA prime and the poxvecror boost was · overcoming antigenic polymorphism. The techniques potentially extended to 44 weeks; in this case 3/5 monkeys were sterilely
(1) focus immune responses on conserved, protective epitopes by protected and the remaining two animals show a delay to the eliminating undesired antigens or domains, (2) provide a strategy first day of parasitemia. 45 Based on these results it would be of for inducing, from one vaccine construct, a broadly neutralizing interest to develop and test a similar multi-antigen, multi-stage immune response targeting a highly polymorphic antigen, and vaccine in humans. in the case of epitope strings (3) offer a strategy for combining One of the critical factors associated with the combination different antigens from the same or different stages of the malaria of antigens is assuring that the selected multi-antigen mixture parasite life cycle. Antigen combination is further discussed in is internally compatible. Elegant studies immunizing mice with the next section. 40 and by the fact that lOOo/o protec-and that this may have been related to competition among the tion can be induced by the RAS vaccine in tolerized mice unable CMV IE promoters used to drive transgene expression. 48 to mount any immune response to CSP. 41 Another way to combine antigens while potentially avoiding Additional support for the concept of a multi-antigen vac-antigenic _<;:~mp~tition is epitope s~rings, as discussed in the precine £mc!s from the fact r_bat Il}alaria vaccine-candidates-base~-ceding section. Tw.o such-·poly-epitope strings. representing mulon sing~~igenihav~een po~~ly efficacimiS, wi~h ~he ~~ep:=· t~J>5 anti!~~ h~ve_~n _testec!.!,n ~he ~i~ ~he.~st,~ns~sting tion of ilie RTS~ vaccine.1hseef on tnebigll 1evel of protec-of epitopes from several cnfferent pre-erydirocync stage P. fa/cition afforded by RAS and by the closely related approach of parum proteins, was designed for co-expression with full length gene-knockout attenuation~-(genetj~ally ar5-enua~d sp9rozo.Ltes, ~ T)i{\P(..SS~7-~T~,~ combine<l a~igen (multi-epitope-TRAP or or GAS), a highly efficacious pt~larja vacci~e will likely need ME-TRAP), has be~n delivered v-ia;DNA, pox and adenovectors to target multiple antigens;-!( is we(l docurrientecr' that genetic -and 1 significantly reduces' liver-stage burden in humans following restriction of host immune responses, sequence polymorphism of P. folciparum sporozoite challenge, showing delays in the onset critical epitopes targeted by T cells and B cells, allelic variation of parasitemia and sometimes sterile protection when delivered and antigenic diversity pose enormous obstacles for the develop-in prime-boost combination, these effects attributed primarily to ment of a malaria vaccine based on only a single antigen. 42 These the TRAP antigen but with the epitope string possibly con cribchallenges may be overcome by the inclusion of multiple target uting (see review by Adrian Hill). The Oxford group has also antigens into a vaccine.
tested a similar polyprotein comprising longer portions of six preDoolan et al. 43 showed that inclusion of two antigens in a erythrocytic stage antigens, but without linkage to TRAP/SSP2. P. yoe/ii DNA vaccine enhanced protection on multiple genetic Although the latter vaccine was safe and moderately immunobackgrounds relative to DNA vaccines based on each of the indi-genic in humans, 49 there was no protection against experimental vidual plasmid components. This work suggests that in a her-sporozoite challenge (A. Hill, personal communication). Two erogenetic human population inclusion of multiple antigens in a other polyepitopc vaccines are nearing clinical testing. The first malaria vaccine may circumvent the genetic restriction imposed is a protein-based construct called FALVAC-1A, being develby the host genetic background and improve vaccine efficacy in oped by the Center for Disease Control and Prevention. 50 The the population. second, originally developed by the US Navy and Epimmune, Data from the P. lmowlesi (Pk) non-human primate challenge Inc, is DNA-based and is now being developed by NIAID for model further supports the contention that candidate malaria clinical testing, currently scheduled for 2010 (A. Mo, personal vaccines should include multiple antigens. 44 • 46 Immunization of communication). rhesus monkeys with a DNA prime/poxvirus boost regimen was partially protective only when the DNA and poxviruses expressed four antigens [PkCSP, Pk thrombospondin-related adhesive protein/ sporozoite surface protein-2 (Pk TRAP/ SSP2), PkAMA 1 and PkMSP1]; substantial delays were observed to >2o/o parasitemia in most animals and 2/5 animals self-cured their parasitemia. In contrast, regimens where both vectors expressed only one antigen (PkCSP) provided only minor delays to >2o/o parasitemia and no self-cures. 44 The protection afforded by this four-antigen,
Adjuvant Design
The spectrum of vaccine design discussed in the introduction, with live-attenuated vaccines at one end and rationally designed subunit vaccines at the other simultaneously defines a spectrum in the requirement for adjuvants. Replicating vaccines generally do not require adjuvants to stimulate potent immune responses, while recombinant protein and peptide-based vaccines invariably do. DNA, viral vectors and virus-like particles possess inherent
In an effort to further strengthen cellular responses, particuproperties for activating the immune system and traditionally larly CDS+ T cell responses, GSK has developed a new formuhave not required adjuvants. However, it is now clear that their lation, composed of liposomes, MPL and QS21, called ASOl. -potency may be improved with novel molecular designs, including In an adjuvant comparison study in rhesus macaques, RTS,S/ co-formulation with a variety of immunostimulatory molecules. ASOl elicited higher RTS,S-specific antibody titers and higher These and other developments are discussed in this section, begin-numbers of antigen-specific IFNy producing cells than RTS,S/ ningwith traditional adjuvants and progressing to novel molecular AS02. 54 Following from these encouraging results, RTS,S/ASOl adjuvants for protein-, peptide-and gene-based vaccines, focusing advanced into Phase l/2b efficacy trials in pediatric populations on molecular design.
and is now transitioning into Phase 3 pre-licensure trials. Another Adjuvants can be represented by several classes of compounds, adjuvant formulation in the GSK repertoire, AS04, is a Toll-like such as microbial products, mineral salts, emulsions, microparti-receptor (TLR) 4 agonist comprised of MPL in alum. AS04 was des, and liposomes, which can exert their function by various, still recently approved for human use in the EU for hepatitis B virus poorly characterized mechanisms of action. Some of the modes of (Fendrix) and human papilloma virus (Cervarix) vaccines. More action attributed to adjuvants in potentiating immunity, whether recently, AS03, an oil-in-water emulsion, was approved as a cominnate or adaptive, include antigen uptake by antigen presenting ponent of a pre-pandemic H5Nl vaccine (Prepandrix). cells, upregulation of antigen presentation and localization to the Montanides are biodegradable emulations containing squalene draining lymph node, increased cellular distress and the anti-and mannide-monooleate as emulsifier and have similar physical gen depot effect. After decades of intensive investigations, recent characteristics as incomplete Freunds adjuvant. Some promising advances led to better understanding of the mechanism of action results have been reported in previous malaria vaccine trials 55 • 56 of immunomodulatory compounds as they relate to induction of using Montanide ISA 720 (SEPPI C. Paris, France), possibly due -innate immunity, opening the doorway for improving adjuvant to the slow-release capacity of the inert water-in-oil emulsion and design at the molecular level. immune stimulating effects of its components. Although very Adjuvants for Proteins and Peptides. Only a handful of adju-potent im_~un~logically, results fr_?m more recent malaria trials vant fbr,nulations are,..curre.ntly approved for human-use. 1 In. the-using montanides (ISA 51-andiSA. 720) have-led to-the .£onclusion USA, al~umA'alts ~minum )Ydro~~~ o~ a_lu~i~um _phos::=_· t?~;_, this g~s o! adjuvant mar~a~e li~jte~ P?ten~al f~ f~rther phate, genericanyfeferred to as alum} are die only example ot an development due to ~car:eactogenicity, incluaing the mduction FDA approved adjuvant. Alum has been used extensively over of sterile abscesses and erythema multiformeF· 58 several decades in vaccine fOrmul~tions fo~ dip~theria.l. tetaiJ_US, J __ J;.veQ. as __.d1ese yarious pepjidsfprotein adjuvants are actively pertussis, hepatitis A, hepatiti~ s' and other: infectious agents. developed~ un~erstanding of tho-molecular mechanisms underAlthough able to efficiently-errllance-fiumoral immn"ne responses, -lyirlg their immuti'opot"entiating-'pmperties remains modest. alum is relatively ineffective for inducing cell-mediated immune Development is driven empirically by the safety, immunogenicity responses.
and protection identified in pre-clinical and clinical testing, with In the European Union (EU), MF59, a squalene-based oil-in-purposeful molecular design playing a less central role. Several water emulsion, was recently licensed for a flu vaccine formulation new classes of adjuvants, however, are closely linked to defined (Fluad), representing a second adjuvant approved for human use. molecular pathways. These are best exemplified by TLR agonists, GlaxoSmithKline Biologicals (GSK) is also testing novel adju-discussed in the next section. vants, developing numbered "Adjuvant System" (AS) technolo-TLR agonists. TLRs are pattern recognition receptors found gies that are based on combinations of classical adjuvants, such on different cell types. that recognize specific molecular patterns as aluminum salts, oil-in-water {o/w) emulsions, liposomes and on pathogens like viruses, bacteria, and fungi. 59 -61 TLR agonists immunomodulatory molecules (reviewed in Garcon et al.) .S' The act as potent adjuvants by activating key antigen presenting cells objective is to induce tailored immune responses directed against (APCs), such as dendritic cells (DCs), through their cognate the pathogen. An example is provided by AS02, which has been TLRs. These TLR-dependent pathways up-regulate cytokine tested in several malaria subunit vaccines, including RTS,S, secretion, increase the expression of MHC class II and co-stimuFMPl, FMP2.1 and LSA-NRCY AS02 is an o/w emulsion con-latory molecules, and promote DC migration to the T cell area of taining MPL (3-0-desacyl-4'-monophosphoryllipid A), an immu-the lymph node. 62 A variety ofimmunostimulatory TLR agonists . nostimulatory molecule derived from the detoxified cell wall of targeting specific TLRs are currently being investigated for use as Gram-negative Salmonella minnesota R595 absorbed to alum, adjuvants in vaccine formulations; for example heat shock proand QS21 (saponin}, derived from Quil A, a fractionate from teins (TLR 4), flagellin (TLR 5), porins (TLR 2), LPS (TLR 4), the bark of Quillaja saponaria, a Chilean tree. AS02 has induced triacylated and diacylated lipopeptides (TLR l/TLR2 and TLR high antibody titers and strong cell-mediated (primarily CD4• T 2/TLR 6, respectively) and oligodeoxynucleotides (ODNs) such cell-mediated) immune responses characterized by high levels of as unmethylated deoxycytosine deoxyguanosine (CpGs) (TLR 9) interferon-gamma (IFNy) secretion. Generally, the immunostim-(reviewed in 63). ulant MPL has been shown to induce the synthesis and release of From the molecular design perspective, TLR agonist deliv--interleukin-2 (IL-2) and IFNy, promoting the generation ofThl ery can be achieved through direct conjugation to an antigen responses, 53 19 -specific antibody responses that cytokines and chemokines, which potentiate antigen-specific were biased toward IgG1 subclass. Inclusion of CpG, a TLR T cell and antibody responses. Moreover, purified adenovector 9 agonist, yielded a shift toward a balanced IgG1/IgG2c ratio serotype 2 (Ad2) hexon protein has been shown to be a potent and higher cellular responses as measured by IFNy secretion. 64 adjuvant for induction of antigen specific responses. 78 Other viral In a recent study, a synthetic, FDA approved topical treatment vectors, including poxvirus 79 • 80 and semliki forest virus, 81 can for skin conditions, imiquimod, a TLR 7 agonist, was shown enhance antigen-specific antibody and T cell responses to co-. to function as a potent adjuvant for eliciting T cell responses. delivered proteins, indicating that these viral vectors also provide Topical application of imiquimod at the site of subcutaneous adjuvant activity. These intrinsic adjuvant properties of DNA and injection of P. folciparum CSP peptides elicited parasite-specific viral vectors facilitate the induction of robust immune responses humoral immunity that protected C57BL mice against mos-to vector-delivered antigens, bypassing the need for adjuvant quito-bite challenge using transgenic rodent parasites express-formulation.
ing P. folciparum CSP repeats. 65 Molecular adjuvants for plasmid and viral vectors. Although ODN CpG motifs are recognized by TLR 9 expressed on pha-plasmid and viral delivery systems do not require adjuvants, cogoendosomes of specialized cell subsets, such as B cells and plas-formulation with an adjuvant can improve the antigen-specific macytoid dendritic cells. CpG ODNs have been primarily used to immune responses induced by these vectors. For example, formuinduce polarized Th1 type immune responses. 66 • 67 Several studies lation of DNA vaccines with CpG oligonucleotides improved the have shown that antigens and CpG ODN must be co-localized immunog~niciry of DNA plasmid~ encoding malaria antigens in to the.{ame ~P.G to gpnerat_e the,most potent and effective-thera:-· mice and _t\-otus monkeysY· 8 .~Co·admini~radon-{)f DNA vacpeutic a_~n·~pe'~ific_!!}tmune r~onse:_~_?e~v~ry ve~icl~s carr_=~ c~~~ wi~yas_mi~_:;exp~si~ i?"'m:~~s .. i:i~ula~~ry ~o.l:cul~s be used to ensure the co·cfelivery of antigens ancf CpG ObN has likewise improved tlie immunogenicity of these vaccmes m to the same APCs, thus leading to significant increased uptake animal models. However, these initial successes have not necesby APCs. These strategies can resu).t in ant~en·specifi~imm!Jne -· s3:riry trj.ns!~ted il}.to humans~FOJ-example, when tested in mice, . responses that are on the order pf 5-to 50~-f~ld 'gr~ater thart for ' co·delivery ofplasmids expressirig-PyCSP and granulocyte·mac· antigen alone. For example;-ih miJ, the' cd·administration--of . . ropKage-colony-stitflularlng factor(GM-CSF) resulted in more CpG and recombinant surface protein·25 (Pfs25) led to a 30·fold robust antibody and T cell responses, as well as better protection improvement in antibody titers and avidities compared to rPfs25 from P. yoelii sporozoite challenge relative to .IJCSP expressing plus alum alone. 68 Results from clinical studies using recombi· plasmid alone. 84 • 85 But, when this combination was evaluated in nant P. folciparum AMA1-C1/Alhydrogel plus CpG 7909 vac-humans, co-delivery ofhuman GM·CSF and P.folciparum anti· cine showed 14-fold-higher AMA1-specific lgG with significantly gen expressing plasmids did not improve T cell responses relative increased in vitro growth inhibitory activity against homologous to the P. folciparum antigen expressing plasm ids alone, and none parasites compared to AMA 1/ Alhydrogel alone. 69 Thus, TLR 9 of the regimens were protective. 86 · agonists are effective immunomodulatory molecules for use as Intervention in costimulatory and inhibitory pathways can vaccine adjuvants. modulate immune responses and represent interesting strate· Adjuvant properties of DNA and viral capsids. In contrast to gies for increasing vaccine responses. The herpes simplex virus protein-based subunit vaccines, viral, bacterial, and DNA vectors glycoprotein D (gO) can enhance T cell and antibody responses generally do not require formulation in adjuvant for induction to fused antigens in the context of DNA and adenovector delivof T cell and antibody responses. However, the intrinsic "dan-ery. 87 gO functions by blocking inhibitory signals between the ger signals" provided by these delivery systems can be improved herpesvirus entry mediator (HVEM) and B-and T-lymphocyte further by molecular engineering. For example, the addition of attenuator (BTLA). This pathway has also been exploited to · unmethylated CpG motifs into the sequence of a DNA vector increase tumor-specific T cell responses. Interactions between expressing a tumor associated antigen has been shown to enhance HVEM and LIGHT (a lymphotoxin-like inducible protein the immunogenicity and efficacy of the vector in a murine mela-that competes with glycoprotein 0 for herpesvirus entry on noma modeF° Conversely, enzymatic methylation ofCpG motifs T cells) provide costimulatory signals for T cell activation.
in a DNA-P. yoelii CSP vector decreased the immunogenicity Adenovector-mediated expression of LIGHT within a tumor of the vector in mice. 71 CpG activation via a TLR 9-dependent can induce tumor-specific T cell responses and eradicate spanmechanism does not appear to be absolutely essential, however. taneous metastases. 88 In a similar way, increased understandMultiple signaling pathways may be involved, including two ing of the signaling pathways that activate the innate immune recently discovered pathways utilizing the DNA sensors DNA-system has potential for enhancing the immunogenicity of dependent activator of interferon regulatory factors (DAI) and DNA and viral vector based vaccines. Recently, coexpression of absent in melanoma-2 (AIM2). 72 As more is learned about the plasmids encoding the TLR-signaling molecules, TRAM and TAK1, were shown to significantly enhance antigen-specific T cell responses in mice following DNA vaccination. 89 Adjuvants can act through a variety of mechanisms. For example, since DNA plasmids injected into the skin or muscle are taken up by cells inefficiently, adjuvants that enhance the uptake of the plasmid into the cell are being evaluated. Panicles that have a diameter of approximately 1 Jlm can be internalized by APCs, such as macrophages and DCs. Therefore, one way to potentially enhance DNA vaccines is to formulate the vector onto a panicle. DNA vaccines formulated onto cationic micropanicles composed of poly lactide-co-glycolide (PLG) or nonionic poloxamer (CRUOOS) particles combined with a cationic surfactant can be internalized by APCs and have been shown to be more potent than unformulated DNA vaccines in pre-clinical animal models ofHIV and CMV. 90 · 91 A DNA-CMV vaccine formulated stronger T cell responses, higher titer antibody responses and more robust protection in mice when delivered by an adenovirus vector. 101 The mechanism for the adjuvant activity of C4bp is not known, but may involve antigen oligomerization or targeting of antigen to antigen presenting cells. Conjugation of malaria
Antigen Delivery
in the CRLlOOS adjuvant has also been shown to be safe and A highly effective malaria vaccine will likely induce robust promoderately immunogenic in a Phase 1 clinical trial.
92 Formulation tective antibody and T cell responses to multiple malaria antigens of DNA vaccines onto PLG and poloxamer particles, however, expressed at multiple stages in the parasite's life cycle. As discussed does not always enhance potency. For example, formulation on in the antigen design section, sequence polymorphism of critical PLG microspheres was tested in the rhesus monkey/ P. knowlesi epitopes targeted by T cells and B cells poses enormous obstacles sporozoite challenge model, using a multistage malaria vaccine for the development of a malaria vaccine based on only a single administered as three priming doses of DNA, with or without antigen. 42 These challenges may be overcome by the inclusion of PLG f~ulation, followed by a poxvector boost. In this study, multiple ~rget .antigens into a va~cine, making antigen combi-PLG fomtul~tioo of ~-he D.NA proved less protective th~ PB$· nation a ~gh priodty for-vaccine developers. Leading-candidate · formula_~4 ~inii5 multiv~leJit D~~-v~c~n~· e~todin~ P.~ p~a~orms ~hat ~e c~g_able of ~~~u<:_ing~p~nses to ..... mu~le..,anti "" )~lasgtidJ. In ~he early 199J)s, )t was discovered that immunization with a plasmid DNA vecror-expressing a flu antigen could "' prot'ecr-mice a:gainst' an-itrfluenza-chaHenge. 107 116 A DNA vector expressing a addition, as mentioned above, viral vector delivery systems progrowth hormone to promote growth and reduce mortality has vide adjuvant activities along with antigen delivery. The leading been developed by VGX Pharmaceuticals for pigs.
117 Although viral vectors for malaria vaccine development are based on poxvithe licensing of these veterinary products has bolstered the belief rus and adenovirus, because of their ability to induce potent antithat DNA vaccines may be possible for humans, the clinical expe-gen-specific immune responses in people, as well as their capacity rience indicates that the potency of these vaccines will need to be to deliver multiple antigens. Other viral vectored vaccines based . dramatically improved before they can be viable in humans.
on alphavirus 122 and yellow fever virus 123 • 124 have induced protec-DNA vaccines can be delivered by several different systems, rive responses in animal models and are also being explored. including a needle and syringe, a needle-free jet injection device Poxvectors. Vectors based on attenuated vaccinia virus (e.g., Biojector®), a particle mediated needle-free device (e.g., NYVAC and modified vaccinia Ankara (MVA), as well as fowlgene gun) or an electroporator. The first DNA-malaria vaccine pox have been developed for malaria vaccines. In murine modto be evaluated in humans was injected IM with a needle and els, vaccination with a NYVAC vector expressing P. berghei CSP syringe. 111 In subsequent trials, DNA-malaria vaccines were also induced CDS• T cell-mediated protection in mice. administered by a gene gun, which uses a needfe-free device to was well toferated at doses ofl x 10 7 and 1 x 108"" plaque formdeliver vaccine coated onto gold beads into the skin. This immunization system, which can aeliver,..the vaccLne di~~ctly .!Jlto c~ls, such as APCs, has been shown 1 to enhance the immunogenicity · and efficacy of DNA vaccine~" 9 A tr~alenr DNA-fl<I H-A vaccine formulated onto gold beads and administered with a gene gun has also been shown to partially protect volunteers against an influenza challenge in a recent Phase lb clinical trialY 0 Another promising way to enhance the potency of DNA vaccines is to deliver these vectors with an electroporator. Electroporation involves the administration of brief electrical pulses immediately after intramuscular injection of the vaccine. -Electroporation can facilitate cellular uptake and has been shown to enhance the immunogenicity and efficacy of DNA vaccines in pre-clinical animal models.~ In fact, the DNA-growth hormone vector used to promote growth and reduce mortality in pigs {see above) is delivered by electroporation. Electroporation has also been used to enhance the immunogenicity of a DNA vector expressing a prostate tumor-tetanus toxin fusion protein in a recent Phase 1 trial. 121 Although the pain associated with electroporation was reported to be brief and acceptable, the universal tolerability of electroporation systems for humans has not been determined. Although the initial promise of DNA vaccines has not yet been fulfilled in humans, recent advances to enhance the potency of these vectors by modifying the plasmid backbone, the transgene, the vaccine formulation or the delivery system, and their potential use in prime-boost regimens may eventually make DNA vectors a viable vaccine platform. Viral vectors. Since malaria vaccines based on viral vectors express high levels of antigen directly in infected cells of the host, antigen is processed and presented to professional antigen ing units and partially protective. One volunteer was completely "' p~Q~ec~~.d a_!}d~ther_e was a sigQjfic)-nt delay in the time to parasite ·patency in!. volunteers that;received-either the low or high dose of -vacclne-cotnpared ""'ith -u'nvaccinared controls.
127
Prime-boost strategies have significant advantages for malaria vaccine development. 128 Poxvirus vectors, FP9 and MVA, have been used together and with DNA and adenovirus vectors in prime-boost vaccination regimens. These studies demonstrated that the prime-boost approach induced more robust immune responses and superior protective responses in rodent models than either regimen alone. In clinical studies, DNA prime-MVA boost studies employing ME-TRAP antigen 129 induced higher levels of T cells and delays to parasitemia following challenge compared to either modality alone.
• 131
Prime-boost vaccination with FP9-MVA (also using ME-TRAP) was safe, immunogenic and partially protective in malaria-naive volunteers receiving experimental challenge, providing sterile protection in a few cases. 132 • 133 The immunogenicity of the FP9-MVA (ME-TRAP) prime-boost vaccine was reduced in adults 134 and children 135 in malaria endemic regions in Kenya and provided no evidence of efficacy. The reasons for this discrepancy are not known. {For more details on this approach see the review in this edition by Hill et al., p. 7S).
Adenovirus vectors. Adenovirus vectors can be engineered to induce broad and protective T cell and antibody responses in animal models, ranging from mouse to non-human primates. 136 -146 Protection from malaria has been observed using adenovectors that express the P. yoelii' 47 142 • 148 or P. berghei 149 CSP antigen in murine models. An Ad5-based HIV vaccine induced antigen-specific CD4 • and CDS· T cell and antibody responses in a majority In ·•llo ~ pro:.ss1o,_ 1mmunvg~n ( •r 1
(-PI an(hor (CSP only)
Promoter t,p.;.
• 14 Vacci nes based on these vectors have advantages from both potency and cost-of goods perspectives. Moreover, this mu lti-gene expression technology is highly flex ible, faciliming rapid substitut ion of different antigens into the multi-gene expressing adenovector after it is developed. A key requirement is that vecrors must have sufficient capacity ro express mu ltiple antigens. We have generated a m ultiply deleted Ad5 vector with room for incorporation of up to 9Kb of foreign sequences, by deletion of three Ad5 early regions, includ ing complete deletions of both ea rly regions I and 4 (El and £4) and a partial deletion of region 3 (E3). E I/E3/E4 -delctcd vectors can be produced in 293-0RF6 cells, which provide complementation for both EI and £ 4 func tions 111 and arc suitable for cGMP manufacturing of adenovcctor preparations free from replication competent adenovirus (RCA). 110 These multiply-defective (Ell E3/E4-deleted) vecrors express much lower levels of adenovirus genes following infection relative to an El/E3-deletcd vector. Consequenrly, immunization of volunteers with E l /£3/ E4-deleted vectors did not induce an expansion of adenovirusGenVec, Inc. has developed a hexon-modified adenovector specific CD4• T cells, 156 a characteristic that could have impor-vaccine platform for malaria vaccine development that avoids rant safety advantages. Recently, we have generated AdS vectors preexisting anti-adenovirus immunity prevalent in human that express high levels of three different pre-erythrocytic stage populations by replacing the AdS HVR sequences with those antigens [CSP, LSAl and cell traversal protein of ookinetes derived from Ad43. This AdS hexon-modified vector is not and sporozoites (CelTOS)] from three different expression cas-neutralized by hexon-specific AdS neutralizing antibodies settes located in the El and E4 regions of the vector genome in vitro using sera from mice, rabbits and human volunteers. (see Fig. 3 ). In preclinical studies in mice, these vectors induced Furthermore, the hexon-modified adenovector that expresses T cell and antibody responses specific for each of these anti-PyCSP is as immunogenic in mice as an unmodified AdS vector gens and the magnitude of these responses was similar to that and can induce robust T cell responses in mice with high levels of control AdS vectors that expressed only one antigen. 6 We are of preexiscing anti-AdS Nab. In addition, the hexon-modified currently applying this multi-gene expression technology to alter-vector effectively boosted AdS vector primed T cell and antinative serotypes of adenovirus where the prevalence of neutraliz-body responses. 177 ing antibodies (NAb) in human populations is very low.
Adenovirus caps ids can also be modified to increase the Adenovector neutralizing antibodies (NAb): prevalence and immunogenicity of the vector. We have demonstrated that the impact on vaccine safety and efficacy. Adenovirus vectors derived introduction of a DC targeting ligand into the fiber improved from AdS have been a leading platform for the generation of molec-DC transduction and antigen-specific T cell responses. 98 Also, ular vaccines. However, forty to sixty percent of the United States B cell epitopes can be inserted into the hexon, fiber and penton population possesses NAb to AdS 99
• 157 and the frequency is even base and displayed on the capsid to induce protective immune higher in Africa, where malaria is endemic.
"
160 In animal models responses in mice. and delivery of heterologous targets derived from various bacte- 170 However, the magnitude of the T cell responses in individuals ria, fungi, viruses and parasites in clinical and veterinary appliwith pre-existing AdS NAb was approximately three-fold lower cations, particularly for gastrointestinal, genital and respiratory than those of the AdS-seronegative volunteers. pathogens. The specific advantages of this approach include (1) The most conservative path forward for adenovirus-based vee-the relative low cost and potential for large scale manufacture tors is to advance vaccines based on alternative serotypes of ade-of target antigen by the "bacterial factory," (2) the presence of novirus where the prevalence of NAb is low. However, finding a natural immunostimulatory molecules, such as LPS and Bagelhighly immunogenic substitute for AdS has not been straightfor-lin, thus obviating the requirement for inclusion of classical ward. To date other serotypes of adenovirus (Ad3S, Adll, Ad26, adjuvants (see section on TLR agonises), (3) sensitivity to antiAd48, Ad49, AdSO and chimpanzee adenovectors) have generally biotics for eradication if indicated and {4) tropism for dendritic under-performed AdS vectors in terms of induced immunogenic-cells and macrophages. Concomitantly, safety considerations icy to their payload antigen. for live attenuated bacterial vaccines focus on the possibility Capsid-modified adenovectors. An alternative strategy for of undesirable systemic dissemination, toxic bacterial byprodavoiding preexisting AdS NAb is to modify the NAb binding ucts (LPS), transmission through contact to either healthy or sites on the AdS capsid. The majority of serotype-specific neutral-immune compromised recipients, and/or the potential for enviizing antibodies recognize determinants on the hexon and fiber ronmental contamination. capsid proteins, 160 • 173 • 174 and hexon-specific neutralizing antibodVaccination using attenuated or killed bacterial vectors that ies appear to be the most prevalent and potent in vivo.' 64 Epitopes serve as antigen vehicles can provide a dual-pronged immunizatargeted by these hexon-specific neutralizing amibodies have been tion strategy --to elicit protective responses against the target mapped to the hypervariable regions (HVR) of the hexon pro-antigen and the vehicle itself. These attenuated bacterial vaccine tein 174 • 175 contained within exposed loops at the surface of the vectors can stimulate potent immune responses by inducing the capsid. Roberts et aL, 2006 demonstrated that it is possible to production of cytokine cascades, including tumor necrosis facreplace each of the 9 HVR of the AdS hexon with those derived tor alpha (TNFcx), IFNy, IL-12 and other proinflammatory from Ad48, a rare adenovirus serotype.' 76 Induction of rransgene-mediators such as N0. 181 The type of immunity elicited by specific immune responses was unaffected by AdS-specific NAb these bacterial vectors is strongly dependent on the bacterium in murine or non-human primate vaccine models.
itself, the route of delivery, as well as other biological indicators associated with the target antigen. For example, the intracel· Previously, ompA genes of Escherichia coli and Shigella dysen1u1ar pathogen Listeria monocytogenes induces both mucosal and teriae have been used to construct enterobacterial surface expressystemic immunity. In murine models, using either E. coli P·gal sion vectors for foreign genes. These fusion constructs have expression or oral administration of L. monocytogenes expressing been widely used as a vector system in experimental models and HIV-1 gag, both mucosal and systemic CDS• cellular immune have been used to transfer target antigens, such as P-galactosiresponses were detected against the target antigens. 182 · 183 dase, foot·and-mouth disease virus (FMDV) and malaria antiNearly two decades ago, an attenuated Salmonella typhi was gens, to the bacterial surface as insertions into OmpA. Several used to elicit a human serologic or cytotoxic T lymphocyte strains of attenuated Shigella, such as S. jlexneri 2a, have been response to a foreign target antigen, P. folciparum CSP. 184 The developed and used in various human clinical trials with good attenuated S. typhi vaccine strain CVD 90S, harboring deletion tolerability. 190 Alternatively, food-grade gram-positive bacteria mutations in aroC and aroD, was shown to be well-tolerated and such as Lactococcus facti have advantages over other attenuated highly immunogenic, eliciting impressive serum antibodies, bacterial vaccine delivery vehicles primarily because of their mucosal lgA and cell-mediated immune responses. A decade inherently greater safety profiles. P. folciparum merozoite surlater, when P. folciparum MSP1 19 was genetically fused to frag· face protein-2 (MSP2) expressed in recombinant L. lactis, either ment C of tetanus toxin and then expressed within attenuated S. intracellularly or covalently anchored to peptidoglycan on the typhi CVD 90S, under nonreductive intracellular bacterial con-cell wall, elicited serum lgG antibodies that reacted with native ditions, chimeric C·MSP1 19 did not fold to form the properly MSP2 on the surface of P. folciparum merozoites, as detected by disulfide bridged epidermal growth factor (EGF) -like domains immunofluorescence. 191 of MSPl. Disulfide dependent monoclonal antibodies failed to A eukaryotic vector has also been used to deliver malaria antirecognize these conformational domains in immunoblots under gens. In one published study, recombinant attenuated Toxoplasma non-denatured conditions on bacterial lysates. These results gondii expressing the P. yoelii CSP proved highly effective in primdemonstrate that proper targeting of the antigen to the appro-ing for CDS• T cell-dependent protective immunity in mice. 192 priate sellular compartment is required. 185 In a recent report, __ . ,
S. entfrfell s~rO¥a~ Typhi §Jrainrwere used for expressi9g and-
• nodominant epitopes fUsed to S. enteric a serovar 1 yph1 cytolysin Vuus·like particles (VL"is) are non·mfecnve, self-assemblmg A (ClyA), which were then used in a heterologous prime·boost viral envelope proteins that are devoid of genetic material. They approach with a DNA-vectored va,s.cine. l~!.erest~ngly, J.llice ~hat " h~'(~ f~tur~s ide';:~nt to b~th. ~n~igen design and to antigen delivwere primed with serovar Typhi 'exP,ressing ;CSP epitopes ·and er-y, on! the one hand providing a-macromolecular scaffolding for boosted with DNA plasmid~ndu.Jd high "'anrillody-titers-to • the1rray df antigerl, and' on the ·orher'triggering host immunity NANP, predominantly lgG2a, and high frequencies of IFNy by taking advantage of natural immunostimulatory properties of producing T cells, while mice receiving only DNA vectored the virus particles that they mimic. vaccine did not induce any antibodies. 186 In a recent published VLPs are highly repetitive and ordered structures that retain report, investigators showed that the genetic detoxification of their morphology similar to infective particles and have been the S. enterica serovai: Typhimurium to improve its safety profile shown to stimulate both potent humoral and cellular immune led to a serendipitous enhancement in antigen-specific immune responses, although they are most effective at stimulating responses. 187 Additional modifications may lead to safer and humoral immunity. enhanced antibody response to all lgG subclasses, as well as the structural components of the VLP are derived). VLPs made an enhanced splenocyte proliferative response against both by the expression of recombinant capsid proteins in baculovirusmalarial epitopes. Combining immunization platforms, for infected insect cells are also under study as potential subunit instance, a prime-boost vaccination strategy that encompasses vaccines against norovirus, rotavirus, hepatitis C virus, hepatitis the benefits of BCG with that of a potent boosting agent like E virus, and human immunodeficiency virus (all homologous MVA, could provide a strategy not only to broaden anti-myco-targets). 194 -197 bacterial immunity, thus reducing the burden of TB disease, Molecular design and engineering have provided the means but also to target malaria, HIV or other concurrent pathogenic for converting these VLPs into platforms for presenting heterinfections.l89 Specifically for TB, when administered in healthy ologous antigens. Principally, the development of such platforms adults, this vaccination strategy induced good CD4 • T cell requires having sufficient structural information to allow for the responses with the capacity to produce effector cytokines and rational design and incorporation of foreign antigens into selfto proliferate following antigen stimulation.
organizing capsid proteins without compromising the capacity to assemble into a VLP. Two basic approaches are used. The first envelope proteins and have been previously developed for many is the creation of a fusion gene expressing the heterologous anti-enveloped-viruses, i.e., semiliki forest, measles, rubella, herpes gen in frame at an appropriate point within the envelope protein simplex, rabies, sindbis, Epstein-Barr, HIV and vesicular stomato result in display on the VLP surface. The resulting product titis virus. All influenza virosomes are unilamellar vesicles having may require mixing with unmodified envelope protein to achieve a diameter of 100-200nm depending on lipid composition. The stable self-assembly, and because of structural constraints may major advantages of virosomes include their immunogenicity in only be able to tolerate the introduction of short foreign peptide the absence of adjuvants and their relatively simple production sequences, such as an antigenic epitope. The second strategy is compared to traditional recombinant protein-based processes. to allow the unmodified envelope protein to assemble into VLPs Virosomes are thought to enhance immune responses against coas the first step, and then heterologous antigen is coupled to the delivered target antigens at multiple levels. Virosomes can interparticle as a second step. The latter technique generally does not act with APCs and B lymphocytes to present the target antigen to interfere with particle stability, allowing decoration with large T lymphocytes to induce both antigen-specific B cell and CD4 • protein domains and even full-length proteins. 198 Whichever T cell responses. Optimally, virosomes can act as carriers of B cell technique is used, the density of the heterologous array on the epitopes, but are also promising for the delivery of carbohydrates, surface is critical to potency. It is hypothesized that array density DNA, siRNA, and drugs. determines the efficiency with which the receptors of inquiring Virosomes can be derived solely from virion lipids or from lymphocytes are cross-linked. As a result, low density arrays, such virion plus supplementary lipids (e.g., lmmunopotentiating as the RTS,S vaccine, are not ideal for inducing immunity in the Reconstituted Influenza Virosomes, IRIV). The final comabsence of adjuvant. The size of the VLP, which varies from 22 position of lipids forming the IRIV can impact not only the to 150nm, is less important for achieving potency than the array physiochemical properties of the resultant virosome, but also density.
immunological properties. IRIV act as antigen carriers through The list of VLPs that have been studied is extensive, and encapsulation or direct association, providing significant flex- • sporozoite [protein) previously shown to induce parasite inhibiHepatitis B virus core prorclan (HBc} was dernatistrated to-be -tor/ activiiies:2°5--A.1though this vactine approach was found to be an effective malaria vaccine platform in preclinical models, where safe and highly immunogenic in a placebo-controlled, randomhigh levels of anti-CS repeat antibodies protected animals from ized clinical Phase 1a safety study conducted at the University malaria challenge. 199 In a recent nonrandomized, non-blinded Hospital of Basel, 206 no sterile protection was observed against a Phase I safety study using ICC-1132 (Malariavax}, a recombinant homologous sporozoite challenge in a subsequent clinical Phase VLP comprised of hepatitis B core antigen engineered to express 2a trial. 207 However, some evidence for the development ofblood the central repeat regions from P. folciparum CSP protein, an stage immunity was reported, as shown by a reduction in paraimmunodominant B [(NANP) 3 ] epitope, an HLA-restricted site growth rates and the observation of crisis forms in the blood CD4 (NANPNVDPNANP) epitope and a universal T cell from some volunteers. A Phase 1b study to evaluate the safety and epitope (amino acids 326-345) was found to be well tolerated, immunogenicity of this vaccine in Tanzanian adults and children but poorly immunogenic when formulated with alhydrogel. antigen, which contains the CSP repeat and C terminal region Another variation on molecularly designed particulate vac-(amino acids 207-395) of the P. folciparum NF54 isolate (307 cines is represented by self-assembling polypeptide nanoparticle clone}. RTS,S is the most advanced malaria vaccine, currently (SAPNs) (Fig. 4 and Box 2). As with VLPs and virosomes, the in pivotal Phase 3 efficacy trials in sub-Saharan Africa. In com-repetitive display ofB cell epitopes on the nanoparticle may lead to bination with GSK proprietary adjuvant systems, this vaccine the induction of a strong humoral immune response. Additional has demonstrated significant protective efficacy against malarial engineering to include the pan-OR T cell epitope, PADRE, disease and severe malaria.
• 202
Adjuvanted RTS,S has been or other relevant helper sequences into the peptide design may shown to induce both a strong antibody response and stimulate influence the immunogenicity of the nanoparticle constructs. Th1 cells-a subset of helper T cells-that participate in cell-These peptide nanoparticles have a reported icosahedral symmemediated immunity. 203 It is the relative success of RTS,S that has try which mimics viral protein caps ids, but can be specifically provided impetus for researchers to consider, develop and evalu-designed to vary in size and the density of the surface array. Since ate alternative particulate-based vaccine platforms.
these peptide nanoparticles are recombinant peptide-based vacAnother particle approach, virosomes, represents a variation cines, the safety risks of live-attenuated vaccines are avoided. In on VLPs. Virosomes are made up of liposomes containing viral studies using an experimental murine model of malaria, SAPNs desig ned to express pepride epiropes from the repeat region of the P. berghei CS P provided nearly 100% prorecrion against sporozoite challenge with P. berghei sporozoires without rhe requ irement for additional adjuvant (Fig. 4) . 208 Furthermore, a SAPN displaying the P. folciparum CSP repeat epitope co mpletely prorecred m ice from challenge usi ng a P. folciparum CS P transgenic P. berglu:i parasite wirhour rhe requirement for add itional adjuvant ( D.
Lanar, personal communication).
Safety of Molecular Vaccines
Establishing safety is rhe mosr impo rtant development o bjective for a malaria vaccine assuming rhat ir offers sign ificant prorecrion. Because the intended rarger populations are hea lthy ind ividua ls, including small children, infa nts, travelers, pregna nt wo men and females entering puberty, rolerabil iry shou ld be acceptable and rhe safery profi le excellenr. The cli nica l assessment of molecular vaccines, as wit h any vaccine, aims to identify ad verse events stemm ing from rhe injected material. Such hazards fa ll into rwo categoriesadverse events rhar arc a nticipated, given w har is known about rhe vaccine, irs form ulation and mechanism of acrion, a nd ad verse events rhar are unexpected. The occurrence of rhe former can be specifica lly so ug ht in cli n ical rri als t hro ugh rest ing or other desig n features builr inro rhe t rials. The larrer cannot be ant icipated a nd dicrares char early st udies shou ld comprise sma ll numbers of vo lunteers su bjecr ro intense fo llow-up in order ro safely identify unknown risks.
. Box l •. Self-assembling. peptide nanopartlcles: Novel vacc.i~e platforms based on virus-like particles are gaining increased interest in the field of . vaccine development. Peptide-based nanoparticles represent an ideal repetitive epltope display system and a platform for the development of highly tailored recombinant vaccines. These peptide nanoparticles have a regular polyhedral symmetry that mimics the Icosahedral architecture of viruses. As such, epitope display approaches have been shown to strongly increase the lmmunogenicity to a given epitope. The fundamental structure of SAPNs Is derived from the molecular design of a monomeric linear polypeptide having about 100 amino acids . (Fig. 4) . Each linear polypeptide is comprised of a pentam~ric and a trlmeric coiled-coil oligomerization domain joined by a two-glycine · residue flexible linker. These alpha-helical coiled-coils represent a common protein oligomerization motif stabilized through hydrophobic interactions occurring along their coiled-coil interface. Both N-and C-termlnal ends of the polypeptides .in the assembled complex are exposed on the surface, allowing for presentation of B cell epitopes in a repetitive antigen display. Peptide epitopes of B cell, T helper, or CTL specifidty can be molecularly in.corporated Into polypeptides by the cloning of their nucleotide sequences into an expression plasmid used to express the polypeptides. Following expression in £. coli, the protein can be purified, refolded, and assembled into nanoparticles having a ·· . diameter of approximately 25 nm. By taking advantage of the increasing knowledge of this structural class of protein motifs, a growing number of biological and therapeutic applications are being COnsidered.lCIB the intrinsic inflammatory properties of the vaccine components, adenovirus-vectored vaccines cause fever and other systemic reactions, generally with doses of 1 x 10 11 particle units or higher. Additional safety concerns are discussed in Box 3.
In addition to these side effects that are consistent with our understanding of the vaccine vector, vaccines may cause a range of unexpected, idiosyncratic reactions based on environmentally-induced or genetic differences among individual recipients which are difficult to predict. For example, the poxvirus platform became the subject of concern when sporadic cases of myocarditis were linked to the administration of replicating vaccinia virus as part of a smallpox immunization campaign (CDC 2003) . However, a subsequent study of volunteers receiving MVA and other non-replicating poxvectors indicated that this concern did not extend to these related poxvirus platforms. Most recently, the Merck STEP trial suggested a link between naturally acquired immunity to AdS (acquired following exposure to wild-type virus earlier in life) and an increased risk of HIV acquisition in uncircumcised men receiving the AdS-vectored HIV vaccine (see Box 3). 211 No plausible mechanism to explain this finding has been established since the STEP trial results were announced in November, 2007. The finding itsdf remains unconfirmed by Mole.cular vaccines based on genetic approaches potentially other studies, as investigators search to identify covariates affectentail fa?ditional haz~ros b>yon~ those of the-injec;te4 ll)ateria)· ing··the r~ults ~f the ST-EP tr-ial ~hat· mar...-have~nKibuted to (vaccine ~ta~, resujti~ro.~;he fa_~:~haf ~~A ~a~~5~pts=.· t~is ,find~~
are syntliesized m vivo Tollowmg mjection and host cell entry, and 1>articularly because Of"'unpredtctedside etfects suchas those these in turn lead to the expression of protein products, includ-just described, each candidate malaria vaccine based on molecing ~oth transgene antigens and )nciden~~JI~ ef-press~d v~~_tor -' u~!J.r. a~proJ.clles .!~eeds 1 to _J>~ e,~_amined careful.ly for tox.icity, protems. Because these product} are expressed mtracellularly, the although ~hen a platform: ts shar-ed by two vaccmes (e.g., tdensafety of a given genetic vaccit(e' cann6t be demonsrt'ated-by clirtr--tical' DNA backbo~es~-adenoviruS' or' poxvirus vector systems, cal studies of the exogenous protein encoded by the transgene, etc.), it is appropriate to cross-reference nonclinical and clinical which will remain primarily in the interstitial tissues following studies in support of safety. This is true, for example, of the cell administration. Thus, a candidate malaria antigen that has been substrate used to produce a vaccine: once safety is demonstrated studied in humans as a recombinant protein requi~es new toxi-and the cell line is qualified for production of vaccines for use in cology studies if subsequently developed as a DNA-or virally-healthy humans (such as for the PER.C6 or 293-0RF6 cell lines vectored vaccine.
used to produce adenovirus vectors), retesting the cell line for Each molecular vaccine platform carries its own particular each vaccine may not be required. In addition to careful evaluasafety risks. For example, viral proteins and nucleic acids present tion in nonclinical studies, the vaccine itself should be designed in viral vectors display a variety of pathogen-associated molecular with safety considerations prominently in mind. For example, patterns that trigger specific host pattern recognition receptors many malaria antigens contain sequences sufficiently similar to to activate the innate immune system. Viral proteins may trigger human sequences (e.g., thrombospondin-like domains 212 • 213 ) that TLR 2 and 4 receptors, viral RNA TLR 3, 7 and 8 receptors, and it is appropriate to conduct BLAST searches** against the human viral DNA the TLR 9 receptor. Each platform can be expected genome in order to avoid sequences in the vaccine that, due to to induce different patterns of immune activation and cytokine homology, might favor integration into the host genome or the release based on its effects on the innate immune system. As an breaking of self-tolerance. example of side effects consistent with these known pathways, Once a new vaccine or previously-tested vaccine based on a we have observed that most recipients of our AdS-vectored new cell substrate has demonstrated safety in appropriate nonclinmalaria vaccine, NMRC-M3V-Ad-PfCA, demonstrate transient ical studies and is advanced to clinical testing, it is important to dose-dependent reductions in circulating neutrophils and lym-evaluate safety in a very small number of individuals, with a delay phocytes, likely due to margination and diapedesis into the inter-before commencing further immunizations. An example where · stitial space of peripherally circulating white cells in response to this procedure was not followed involved the administration of the danger signal and resulting cytokine cascade engendered by TGN1412, a humanized monoclonal antibody designed as an the viral capsid or its DNA. 209 This occurs during the first few agonist to the CD28 receptor on T lymphocytes. Six of the eight days following administration of the vaccine and parallels published data on the side effects of CpG 7909, a TLR9 agonist, when administered subcutaneously. 210 Likely also associated with ** Basic Local Alignment Search Tool Box 3. Adenovector Safety: Each molecular platform, and potentially · each molecular vaccine; is c:haracterizeCI by theoretical safety concerns that may or may not turn out to be significant In vivo. These concerns must be rationally addressed prior to clinical testing, potentially by conducting nonclinical studies, and then monitored closely, to the extent possible, In Phase I studies. Here are several concerns relating to adenovirus vectors: lnteptlon ppteot!al· Although adenovlruses infect a wide range of cell types, their genome remains episomal in the Infected host cell and they lack native integration machinery. A report from the European Medicines Agency dassified adenovirus as a non-Integrating vector. 252 ·However, studies ·have shoWn that replication-incompetent adenoviral· vectors can randomly Integrate ·into host chromosomes, at frequencies of 10-2-10..s per infected cell, when studied in vitro in replicating cells where active selection was used to detect these evenu. 253 • 254 This low rate has limited the usefulness of unmodified, non-replicating adenoviruses as vehicles for effecting permanent gene transfer, but represenu an advantage for their use as vaccine vectors where long-term expression Is not required. The risk of insertional mutagenesis in neighboring genes resulting from Integration evenu would be expected to be lower than the rate of integration, since only a small proportion of integration · evenu would be expected to result in nu:.cagenesis. · Latenc;x and transformation· Wild-type adenoviruses can remain latent In tissues and have been detected in tumors as well as in normal tissues, although there is no definitive evidence that vectors such as AdS (Group C adenovlruses) play a causative role in human cancer,us.m nor Is there evidence of germline transductlon. 1 60. 261 Adenovlruses are also reported to have transforming (immortalizing) potential in vitro, including Group C adenoviruses.26l.l6l One approach to addressing this concern is to delete the regions of the virus associated with transformation, notably the. EIA and E I B genes. 264 Most adenovectors currently . in the clinic have the E r region of the vf..Us removed and replaced with the expression cassette for the transgene. The AdPfS (Fig. 3) vaccine also has the E4 and portions of the E3 genes removed.
Merck SJEP Trial: The findings in the STEP trial (see text and Buchbinder et al. 211 ) raise central questions about the safety of adenovirus vectors. Do they indeed Increase the risk of HIV infection In those seropositive for anti-Ad neutralizing antibodies? Since the signal was detected only in uncircumcised men, could It relate, for example to the presence of CD4+ T cells and virus Incubating under the foreskin following exposure through sexual contact, and thus remain restricted . to this age, ·sex ancl risk-groupl Is the risk peculiar to AdS or would it · apply to all viral vectors? Would the risk disappear with adenovectors that express significandy lower levels of viral proteins than the Merck vector, such as the EIIE3/E4-deleted AdPfS vector? Until these and additional questions are answered, it will be prudent to restrict the testing of adenovectors to seronegative individuals or, if seropositive, to those individuals who know and have control over their risk for HlV 1 exposure.
· healthy adult subjects receiving the injection in an initial immunization session developed multi-organ failure associated with a systemic inflammatory response syndrome and nearly died, despite reportedly unremarkable toxicity observed in rabbits and monkeys receiving up to 500 times the human dose. 214 Although this was a therapeutic monoclonal antibody, not a vaccine, the principle applies equally to molecular vaccines.
With these considerations in mind, molecular vaccines have generally been well-tolerated and safe in humans, both malarianaive research subjects tested in the US and Europe, and in malaria-exposed residents of endemic areas. This includes vaccines based on DNA, 184 Theoretical concerns regarding the induction of autoimmunity (e.g., anti-double stranded DNA antibodies), integration into the host genome or germline, or persistence of transgene expression with resulting untoward effects, have not materialized. As the electroporation of DNA plasmids to increase cellular uptake and expression undergoes clinical testing, the question of integration into host genomic DNA must remain open, as electroporation may increase this risk. 228 Viral vectors appear more reactogenic than naked DNA, but still carry an acceptable tolerability profile. The most extensively studied of vi rally vectored vaccine platforms, MVA, has been administered as a prevention for smallpox (thus without transgenes) to over 120,000 previously unvaccinated individuals, including elderly individuals, alcoholics and others with compromised immunity. Only a small proportion showed any systemic side effects, such as fever and there were no indications of serious reactions associated with the vaccine. 229 In addition to these clinical studies, a substantial body of literature has been accumulated regarding animal toxicology, biodistribution and geno~_ic in!egration (or lack tjtereof) of gene-based vaccines to-support the good-safctypron~es obs~rved in hutnansP 69 and this in turn led to identification and testing of less allergenic formulations.
236 A major step in establishing safety of immunomodulatory adjuvant systems occurred with the co-administration of plasmids encoding human GM-CSF to healthy adults as an immunostimulant to improve the potency of the pentavalenr MuStD05 malaria vaccine {a mixture of five plasmids encoding pre-erythrocytic stage antigens). 86 Although a porentially adverse inflammarory response might have been anticipated following the injection of this human cytokine, the vaccine/adjuvant combination was well-tolerated, even if non-protective. 237 One of the ways that the safety profile of this vaccine was assessed pre-clinically was to immunize mice with the vaccine in a standard toxicology study, but instead of co-administration with a plasmid encoding human GM-CSF, the mice were given a plasmid encoding murine GM-CSF to better reproduce a hostappropriate inflammatory response. 231 This illustrates that careful study design based on purported mechanism may be helpful in improving the predictive ability of non-clinical studies. The case ofTGN1412 monoclonal antibody cited above provides another example where potential species-specific toxicity profiles misled investigators, with benign results in animal models failing to predict life-threatening toxicity in humans. 214 This principle is an important consideration for the immunomodulatory components of a vaccine, since many of these compounds act via a speciesspecific mechanism.
Potential rare side effects of molecular vaccines will remain a major concern, as their identification ultimately relies upon the larger sample sizes associated with Phase 3 testing and licensure, milestones not yet achieved by any gene-based vaccine. Postmarketing surveillance, key to this process, will be hampered for malaria vaccines, since many of the target populations reside in resource-poor countries lacking the capacity to adequately monitor and report serious adverse events post licensure.
Looking to the Future to recognize, either because of diversionary strategies or for other reasons, such as host mimicry (hiding under the umbrella of selftolerance), or because evolution has favored amino acid sequences that bind poorly to MHC molecules. For example, the parasite exposes immunodominant domains (such as the NANP repeat of P. folciparum CSP) that, while inducing partially protective immune responses, also may serve as decoys diverting the immune response away from subdominant responses that are potentially more protective. Moreover, epitopes may have evolved to stimulate regulatory T cell responses, suppressing rather than enhancing immunity. The success of molecular vaccines for malaria will Many vaccine developers are currently focusing on molecular vac-likely require progress in many areas, including the identification cines. One of the most important reasons for this is their potential of new antigens, the optimization of vaccine platforms able to for improved safety and efficacy, especially for the difficult infec-deliver multiple antigens, the development of new, safer adjuvants tious disease targets, such as malaria, HIV and tuberculosis, where and immunostimulants, and the redesign of antigenic targets to traditional approaches have failed to deliver effective vaccines or improve immunogenicity. carry unacceptable safety risks. It is comforting for the customer and satisfying for the vaccine developer to conceive and build a vacAcknowledgements cine based on known biological mechanisms and precisely defined We thank Ashley Birkett for assistance in generating the manumolecular targets. This type of immunogen can be manufactured script outline, Doug Brough for his review of the entire manuscript, according to tightly controlled, reproducible processes, yielding a Sheetij Dutra, Yimin Wu and Shannon Takala for their reviews of drug substance where nearly every attribute is defined. Ultimately, the sections describing their laboratory's work on AMA1, David the COI).lpiehe~sive unde~standing intrinsic to a well-conceived L~nar ~or!is reyiew of the s~ction~ on SAPNs, Blaise Genton f~r molec6li!Yva~cmesho}lld lll)prov~both safety and effu;acy, ~hereby-h1s·Fev1ew~£the update on.vupsomes and qmhan,-Bendey for h1s meeting tht;Jna~oals 6>r vaccin~evelopersr ' .
--~ review of~t~ legend fpr F~ure 2. We-ate grateful to wry Brice, A. re-.:.engfr<eered immtr-. . : Wdtbroek for the utigina1-figure of'the' PfAMA1 crystal structure nogen can be placed into the existing expression cassette, and the and legend in Figure 2 and to David Lanar for permission to pubimproved product manufactured by the same processes as the orig-lish the SAPN diagram and murine protection data in Figure 4 . inal product.
The study protocols for the clinical trials discussed in the Ultimately, however, molecular vaccines may be needed because manuscript that were performed by the US Navy or US Army they are the only way to protect against difficult pathogens, includ-were approved by the Naval Medical Research Center or Walter ing chronic infections like malaria and HIV, where the pathogen Reed Army Institute of Research Institutional Review Boards, successfully manipulates the immune system to its advantage, respectively, in compliance with all applicable Federal regulations as well as emerging threats, such as pandemic influenza. While governing the protection of human subjects. Likewise, the aniattempting to design and license molecular vaccines for these mal experiments reported herein that were conducted by the US pathogens, significant obstacles have been encountered, such as Navy or US Army were conducted in compliance with the Animal antigenic polymorphism, the existence of redundant molecular Welfare Act and in accordance with the principles set forth in the · pathways, and host genetic restriction. These obstacles in turn "Guide for the Care and Use of Laboratory Animals," Institute have led to major improvements in molecular technologies. We of Laboratory Animals Resources, National Research Council, now have multiple promising platforms to optimize, a variety of National Academy Press, 1996. TLR is a military service member excellent models for testing, and burgeoning knowledge of innate and EA is an employee of the U.S. Government. The work ofTLR and acquired immune responses to inform development efforts. and EA was prepared as part of official government duties. Tide 17 As illustrated in this review, malaria is playing a crucial role in U.S.C. §105 provides that 'Copyright protection under this tide is the development of molecular vaccines. Many novel technologies, not available for any work of the United States Government.' Tide such as the evaluation of a plasmid encoding human GM-CSF in 17 U.S.C. §101 defines a U.S. Government work as a work prepared . healthy adults, have first been tested against Plasmodium. Malaria by a military service member or employee of the U.S. Government has the advantage of providing an ethical human challenge model, as part of that person's official duties. The work of KL and TLR presenting vaccine developers with rapid feedback regarding effi-was supported by work unit number 6000.RADI.F.A0309. cacy, thereby accelerating the testing of new vaccine concepts. The views expressed in this article are those of the authors Looking to the future, one of the main challenges for vaccine and do not necessarily reflect the official policy or position of developers is the complexity of malaria proteins as antigens. The the Department of the Navy, the Department of the Army, the best malaria antigens may prove difficult for the immune system Department of Defense, or the U.S. Government. I.
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